BACKGROUND: Two new formulations of an investigational 15-valent pneumococcal conjugate vaccine (PCV15-A and PCV15-B) were developed using 2 different protein-polysaccharide conjugation processes and evaluated in separate phase I/II studies (NCT02037984 [V114-004] and NCT02531373 [V114-005]) to assess optimal concentrations of pneumococcal polysaccharide (PnPs) and Aluminum Phosphate Adjuvant. METHODS: Various lots of PCV15-A and PCV15-B containing different concentrations of PnPs and/or adjuvant were compared to PCV13 in young adults and infants. Adults received single dose and infants received 4 doses at 2, 4, 6, and 12-15 months of age. Adverse events (AEs) were collected after each dose. Serotype-specific immunoglobulin G (IgG) concentrations and opsonophagocytic activity (OPA) were measured prior and 30 days postvaccination in adults, at 1 month postdose 3 (PD3), pre-dose4, and postdose 4 (PD4) in infants. RESULTS:Safety profiles were comparable across vaccination groups. At PD3, serotype-specific IgG GMCs were generally lower for either PCV15 formulation than PCV13 for most shared serotypes. PCV15 consistently elicited higher antibody responses to the 2 serotypes unique to the vaccine (22F and 33F) and serotype 3 for which PCV13 was shown to be ineffective. Except for serotypes 6A and 6B, no dose-response effect was observed with increasing concentrations of PnPs and/or adjuvant. CONCLUSION:PCV15 is safe and induces IgG and OPA responses to all 15 serotypes in the vaccine. No significant differences in antibody responses were observed with increases in PnPs and/or Aluminum Phosphate Adjuvant.
RCT Entities:
BACKGROUND: Two new formulations of an investigational 15-valent pneumococcal conjugate vaccine (PCV15-A and PCV15-B) were developed using 2 different protein-polysaccharide conjugation processes and evaluated in separate phase I/II studies (NCT02037984 [V114-004] and NCT02531373 [V114-005]) to assess optimal concentrations of pneumococcalpolysaccharide (PnPs) and Aluminum Phosphate Adjuvant. METHODS: Various lots of PCV15-A and PCV15-B containing different concentrations of PnPs and/or adjuvant were compared to PCV13 in young adults and infants. Adults received single dose and infants received 4 doses at 2, 4, 6, and 12-15 months of age. Adverse events (AEs) were collected after each dose. Serotype-specific immunoglobulin G (IgG) concentrations and opsonophagocytic activity (OPA) were measured prior and 30 days postvaccination in adults, at 1 month postdose 3 (PD3), pre-dose4, and postdose 4 (PD4) in infants. RESULTS: Safety profiles were comparable across vaccination groups. At PD3, serotype-specific IgG GMCs were generally lower for either PCV15 formulation than PCV13 for most shared serotypes. PCV15 consistently elicited higher antibody responses to the 2 serotypes unique to the vaccine (22F and 33F) and serotype 3 for which PCV13 was shown to be ineffective. Except for serotypes 6A and 6B, no dose-response effect was observed with increasing concentrations of PnPs and/or adjuvant. CONCLUSION:PCV15 is safe and induces IgG and OPA responses to all 15 serotypes in the vaccine. No significant differences in antibody responses were observed with increases in PnPs and/or Aluminum Phosphate Adjuvant.
Authors: Shamez N Ladhani; Sarah Collins; Abdelmajid Djennad; Carmen L Sheppard; Ray Borrow; Norman K Fry; Nicholas J Andrews; Elizabeth Miller; Mary E Ramsay Journal: Lancet Infect Dis Date: 2018-01-26 Impact factor: 25.071
Authors: Richard McFetridge; Ajoke Sobanjo-Ter Meulen; Steven D Folkerth; John A Hoekstra; Michael Dallas; Patricia A Hoover; Rocio D Marchese; Donna M Zacholski; Wendy J Watson; Jon E Stek; Jonathan S Hartzel; Luwy K Musey Journal: Vaccine Date: 2015-04-23 Impact factor: 3.641
Authors: Katherine L O'Brien; Lara J Wolfson; James P Watt; Emily Henkle; Maria Deloria-Knoll; Natalie McCall; Ellen Lee; Kim Mulholland; Orin S Levine; Thomas Cherian Journal: Lancet Date: 2009-09-12 Impact factor: 79.321
Authors: David Greenberg; Patricia A Hoover; Timo Vesikari; Christopher Peltier; David C Hurley; Richard D McFetridge; Michael Dallas; Jonathan Hartzel; Rocio D Marchese; Beth-Ann G Coller; Jon E Stek; Chitrananda Abeygunawardana; Michael A Winters; John E MacNair; Narahari S Pujar; Luwy Musey Journal: Vaccine Date: 2018-09-21 Impact factor: 3.641
Authors: Robert K M Choy; A Louis Bourgeois; Christian F Ockenhouse; Richard I Walker; Rebecca L Sheets; Jorge Flores Journal: Clin Microbiol Rev Date: 2022-07-06 Impact factor: 50.129
Authors: Annelies Müller; Jackie Kleynhans; Linda de Gouveia; Susan Meiring; Cheryl Cohen; Lucy Jane Hathaway; Anne von Gottberg Journal: Emerg Infect Dis Date: 2022-01 Impact factor: 6.883
Authors: Ann Thanawastien; Kelsey E Joyce; Robert T Cartee; Laurel A Haines; Stephen I Pelton; Rodney K Tweten; Kevin P Killeen Journal: Vaccine Date: 2020-06-10 Impact factor: 3.641
Authors: Heather L Platt; David Greenberg; Bruce Tapiero; Robert A Clifford; Nicola P Klein; David C Hurley; Tulin Shekar; Jianing Li; Kim Hurtado; Shu-Chih Su; Katrina M Nolan; Camilo J Acosta; Richard D McFetridge; Kara Bickham; Luwy K Musey Journal: Pediatr Infect Dis J Date: 2020-08 Impact factor: 3.806
Authors: R K Lucinde; G Ong'ayo; C Houlihan; C Bottomley; D Goldblatt; J A G Scott; K E Gallagher Journal: Vaccine Date: 2021-07-31 Impact factor: 4.169
Authors: Johnna Perdrizet; Carlos Felipe S Santana; Thais Senna; Rodrigo Fernandes Alexandre; Rodrigo Sini de Almeida; Julia Spinardi; Matt Wasserman Journal: Hum Vaccin Immunother Date: 2020-09-23 Impact factor: 3.452